AR015237A1 - A COMPOSITION OF MODIFIED TUMOR CELL MEMBRANES WITH HAPTEN, METHOD FOR OBTAINING AND USE. - Google Patents
A COMPOSITION OF MODIFIED TUMOR CELL MEMBRANES WITH HAPTEN, METHOD FOR OBTAINING AND USE.Info
- Publication number
- AR015237A1 AR015237A1 ARP990100710A ARP990100710A AR015237A1 AR 015237 A1 AR015237 A1 AR 015237A1 AR P990100710 A ARP990100710 A AR P990100710A AR P990100710 A ARP990100710 A AR P990100710A AR 015237 A1 AR015237 A1 AR 015237A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor
- composition
- tumor cell
- cells
- membranes
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title abstract 6
- 239000012528 membrane Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 230000004044 response Effects 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 230000005951 type IV hypersensitivity Effects 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion de membranas celulares tumorales, método para obtenerlas y su uso, donde la composicion comprende membranas aisladas de células tumoralesoriginadas a partir de tumores humanos o de animales domésticos que han sido modificadas con un hapteno. Cada dosis de membranas celulares tumorales humanashaptenizadas corresponden a un máximo de 7,5 x 10(exp 6) células equivalentes (c.e.). La composicion puede ser incorporada a una vacuna, util para eltratamiento del cancer. La composicion tiene la propiedad de que cuando se administra a un mamífero que posee un tumor maligno del mismo tipo que la célulatumoral, produce linfocitos T que se infiltran en el tumor del mamífero, provoca una respuesta inmuno inflamatoria contra el tumor del mamífero y provoca unarespuesta de hipersensibilidad de tipo retardada al tumor del mamífero. Métodos anteriores de inmunoterapia del cancer, basados en células tumorales intactas oen antígenos tumorales aislados adolecen de niveles bajos de respuestaclínica. La composicion basada en la haptenizacion de las membranas de las célulastumorales ha mostrado niveles promisorios de respuesta clínica.A composition of tumor cell membranes, method of obtaining them and their use, where the composition comprises membranes isolated from tumor cells originating from human tumors or from domestic animals that have been modified with a hapten. Each dose of humanized human tumor cell membranes corresponds to a maximum of 7.5 x 10 (exp 6) equivalent cells (c.e.). The composition can be incorporated into a vaccine, useful for the treatment of cancer. The composition has the property that when administered to a mammal that has a malignant tumor of the same type as the tumor cell, it produces T lymphocytes that infiltrate the mammalian tumor, causes an immune-inflammatory response against the mammalian tumor and causes a response of delayed type hypersensitivity to the mammalian tumor. Previous methods of cancer immunotherapy, based on intact tumor cells or isolated tumor antigens suffer from low levels of clinical response. The composition based on haptenization of the membranes of the tumoural cells has shown promising levels of clinical response.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2501298A | 1998-02-17 | 1998-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015237A1 true AR015237A1 (en) | 2001-04-18 |
Family
ID=21823570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100710A AR015237A1 (en) | 1998-02-17 | 1999-02-23 | A COMPOSITION OF MODIFIED TUMOR CELL MEMBRANES WITH HAPTEN, METHOD FOR OBTAINING AND USE. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1054690A2 (en) |
| JP (1) | JP2002502880A (en) |
| KR (1) | KR20010041018A (en) |
| CN (1) | CN1291105A (en) |
| AR (1) | AR015237A1 (en) |
| AU (1) | AU2686999A (en) |
| BR (1) | BR9907912A (en) |
| CA (1) | CA2320969A1 (en) |
| IL (1) | IL137791A0 (en) |
| PL (1) | PL342856A1 (en) |
| WO (1) | WO1999040925A2 (en) |
| ZA (1) | ZA991245B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1067960A2 (en) * | 1998-04-09 | 2001-01-17 | Thomas Jefferson University | A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| US6248585B1 (en) | 1998-11-19 | 2001-06-19 | Thomas Jefferson University | Compositions for preserving haptenized tumor cells for use in vaccines |
| JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
| US7297330B2 (en) | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| US7612251B2 (en) | 2000-09-26 | 2009-11-03 | Pioneer Hi-Bred International, Inc. | Nucleotide sequences mediating male fertility and method of using same |
| CA2489076A1 (en) | 2002-06-10 | 2003-12-18 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| WO2017189281A1 (en) * | 2016-04-27 | 2017-11-02 | The Regents Of The University Of Michigan | C3d cellular and acellular vaccines for the prevention and treatment of cancer |
| CN115137814A (en) * | 2022-07-01 | 2022-10-04 | 可蓝赛生物医药(上海)有限公司 | Tumor vaccine adjuvant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086134A (en) * | 1973-09-18 | 1978-04-25 | University Of Glasgow | Method for preparation of vaccine against feline leukemia |
| AU727316B2 (en) * | 1995-06-07 | 2000-12-07 | Thomas Jefferson University | Hapten modified tumor cell extract and methods of treating or screening for cancer |
-
1999
- 1999-02-17 IL IL13779199A patent/IL137791A0/en unknown
- 1999-02-17 AU AU26869/99A patent/AU2686999A/en not_active Abandoned
- 1999-02-17 PL PL99342856A patent/PL342856A1/en not_active Application Discontinuation
- 1999-02-17 WO PCT/US1999/003536 patent/WO1999040925A2/en not_active Application Discontinuation
- 1999-02-17 BR BR9907912-7A patent/BR9907912A/en not_active Application Discontinuation
- 1999-02-17 ZA ZA9901245A patent/ZA991245B/en unknown
- 1999-02-17 EP EP99907137A patent/EP1054690A2/en not_active Withdrawn
- 1999-02-17 JP JP2000531176A patent/JP2002502880A/en not_active Withdrawn
- 1999-02-17 CN CN99803065A patent/CN1291105A/en active Pending
- 1999-02-17 KR KR1020007009049A patent/KR20010041018A/en not_active Application Discontinuation
- 1999-02-17 CA CA002320969A patent/CA2320969A1/en not_active Abandoned
- 1999-02-23 AR ARP990100710A patent/AR015237A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1054690A2 (en) | 2000-11-29 |
| JP2002502880A (en) | 2002-01-29 |
| KR20010041018A (en) | 2001-05-15 |
| WO1999040925A2 (en) | 1999-08-19 |
| BR9907912A (en) | 2000-10-24 |
| WO1999040925A3 (en) | 1999-10-21 |
| CN1291105A (en) | 2001-04-11 |
| CA2320969A1 (en) | 1999-08-19 |
| PL342856A1 (en) | 2001-07-16 |
| ZA991245B (en) | 1999-08-18 |
| AU2686999A (en) | 1999-08-30 |
| IL137791A0 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Talmadge et al. | Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors | |
| CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
| ATE389712T1 (en) | CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENE CELLS | |
| EP2377548A3 (en) | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy | |
| ATE90877T1 (en) | VIRUS-MODIFIED TUMOR VACCINE FOR THE IMMUNOTHERAPY OF TUMOR METASTASES. | |
| GR3036951T3 (en) | Cells with multiple altered epitopes on a surface antigen for use in transplantation | |
| ES2160570T3 (en) | MUTANTS OF PNEUMOLISIN AND VACCINES OF PNEUMOCOCES MANUFACTURED FROM THE SAME. | |
| EA199800272A1 (en) | FACTOR, STIMULATING DENDRIT CELLS | |
| DE69433590D1 (en) | CELLULAR VACCINE AND THEIR USE FOR TREATING MALIGNAS, SOLID TUMORS | |
| AR004341A1 (en) | VACCINES AGAINST TUMORS AND PROCEDURE FOR THEIR PRODUCTION. | |
| JP2008512491A5 (en) | ||
| AR015237A1 (en) | A COMPOSITION OF MODIFIED TUMOR CELL MEMBRANES WITH HAPTEN, METHOD FOR OBTAINING AND USE. | |
| Raz et al. | Isolation of plasma membrane fragments and vesicles from ascites fluid of lymphoma-bearing mice and their possible role in the escape mechanism of tumors from host immune rejection | |
| ATE418344T1 (en) | FUSION CELLS AND CYTOKINE COMPOSITIONS FOR TREATING DISEASES | |
| ATE309329T1 (en) | HYPERTHERMIA AND IMMUNOTHERAPY FOR LEUKEMIA, LYMPHOMAS AND SOLID TUMORS | |
| DE60130634D1 (en) | IDENTIFICATION OF ANTIGENIC PEPTIDES BY CYTOTOXIC T-LYMPHOCYTIVES ACTIVATED BY DENDRITIC CELL HYBRIDS | |
| Kopf | Host defenses against malignant melanoma | |
| Ponzio et al. | Dependence of lymphoma growth on ‘reversed immunological surveillance’ | |
| Testorelli et al. | In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas | |
| Monjardino et al. | Polypeptide profile of HBsAg excreted by a human hepatoma cell line | |
| Maestroni et al. | Immunoreactivity of long lived H-2 incompatible irradiation chimeras (H-2d leads to H-2b). | |
| Grogan et al. | Increased survival of xenogeneic tumor in thymectomized hosts | |
| LESHEM et al. | Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture | |
| WO2001077301A1 (en) | Tumor cells transformation process | |
| Montgomery | Restricted isoelectric spectra of anti-DNP antibodies produced by neonatal rabbits |